Yahoo Finance

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneous T-cell lymphoma, CTCL. The confirmatory Phase 3 study builds on the previous statistically significant Phase 3 study, as well as a recent successful comparative study and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on SNGX:

• Soligenix announces analysis from protocol HPN-CTCL-04

• Soligenix forms European Medical Advisory Board

• Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s Disease

• Soligenix reports Q3 EPS (78c) vs. ($2.56) last year

• Soligenix granted Hong Kong patent for production of synthetic hypericin